Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Recent Reports in RVO

Retinal Ven Tıkanıklığında Yeni Gelişmeler ve Güncel Tedavi Seçenekleri

Pages
81–95
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review article summarizes evidence from randomized controlled trials evaluating treatment options.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinal vein occlusion (RVO) is one of the most common occur- ring retinal vascular abnormalities.
📊
Key Findings & Data:The laser photo- coagulation has been shown to decrease the risk of visual loss and improve visual acuity (VA), however, visual recovery with the laser is usually slow and incomplete.
💡
Conclusion & Impact:This review article summarizes evidence from randomized controlled trials evaluating treatment options.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinal vein occlusion (RVO) is one of the most common occur- ring retinal vascular abnormalities. The management of macular edema that is the most common cause of visual loss in patients with BRVO has changed considerably over time. The laser photo- coagulation has been shown to decrease the risk of visual loss and improve visual acuity (VA), however, visual recovery with the laser is usually slow and incomplete. It has made important contribu- tions in improving the development of recent intravitreal agents, especially in anti-vascular endothelial growth factors (VEGF). Randomized clinical trials have reported optimal results with an- ti-VEGF agents (ranibizumab, bevacizumab, and afl ibercept) com- pared to laser therapy. This review article summarizes evidence from randomized controlled trials evaluating treatment options.

Özet

Retina ven tıkanıklığı (RVO) en sık rastlanan retinal vasküler anomalilerden biridir. BRVO’ lu hastalarda görme kaybının en sık nedeni olan maküla ödemi tedavisi zamanla değişim göster- miştir. Lazer fotokoagülasyonun görme kaybı riskini azalttığı ve görme keskinliğini arttırdığı gösterilmiştir, ancak lazer ile görsel iyileşme genellikle yavaş ve yetersizdir. İntravitreal ajanlardaki, özellikle anti-vasküler endotelyal büyüme faktörlerinin (VEGF) son yıllardaki gelişimi görmenin iyileştirilmesine önemli kat- kılar sağlamıştır. Randomize klinik çalışmalarda, anti-VEGF ajanların (ranibizumab, bevacizumab ve afl ibercept), lazer teda- visine kıyasla daha iyi sonuçlar sağladığı bildirilmiştir. Bu der- lemede, tedavi seçeneklerini değerlendiren randomize kontrollü çalışmaların sonuçları özetlenmektedir.

🔖

Cite This Article

ŞAHİN, Ö. (2017). Recent Reports in RVO. Retina-Vitreus, Cilt: 26 - Sayı: 0, 81–95. https://ajindex.com/articles/304856

References (7)

  1. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and manag ement. J Thromb Haemost 2010; 8(9): 1886-1894.
  2. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90(5): 627-639. Baseline and early natural history report. The Central Vein Occ- lusion Study. Arch Ophthalmol 1993; 111(8): 1087-1095.
  3. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Moun- tains Eye Study. Arch Ophthalmol 2006; 124(5): 726-732.
  4. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126(4): 513-518.
  5. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313-319 e311. Cehofski LJ, Kruse A, Kjaergaard B, Stensballe A, Honore B, Vorum H. Proteins involved in focal adhesion signaling pathways are diff erentially regulated in experimental branch retinal vein occlusion. Exp Eye Res 2015; 138: 87-95.
  6. Coscas F, Glacet-Bernard A, Miere A, Caillaux V, Uzzan J, Lupi- di M et al. Optical Coherence Tomography Angiography in Reti- nal Vein Occlusion: Evaluation of Superficial and Deep Capillary Plexa. Am J Ophthalmol 2016; 161: 160-171 e161-162. Bertelsen M, Linneberg A, Christoff ersen N, Vorum H, Gade E, Larsen M. Mortality in patients with central retinal vein occlusi- on. Ophthalmology 2014; 121(3): 637-642.
  7. Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for sys- temic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97(11): 1543-1548. Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1996; 114(5): 545- 554. Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost 2015; 13(7): 1254- 1263. Rehak M, Rehak J, Muller M, Faude S, Faude F, Siegemund A et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008; 99(5): 925-929. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H